Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Edgewise Therapeutics, Inc. (EWTX : NSDQ)

• Company Description    Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States. Number of Employees: 146

• Price / Volume Information    Yesterday's Closing Price: $43.07 Daily Weekly Monthly 20 Day Moving Average: 1,026,772 shares Shares Outstanding: 108.60 (millions) Market Capitalization: $4,677.58 (millions) Beta: 0.32 52 Week High: $48.40 52 Week Low: $13.69 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.39% -2.96% 12 Week 22.32% 19.72% Year To Date 73.56% 53.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1715 38TH ST - BOULDER,CO 80301 USA ph: 720-262-7002 fax: - ir@edgewisetx.com http://www.edgewisetx.com

• General Corporate Information    Officers Kevin Koch - President; Chief Executive Officer and Director Peter Thompson - Chairman and Director Michael Nofi - Chief Financial Officer Alan Russell - Chief Scientific Officer and Director Laura A. Brege - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 28036F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 108.60 Most Recent Split Date: (:1) Beta: 0.32 Market Capitalization: $4,677.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 10.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -55.88% vs. Previous Quarter: -15.22% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -39.01 03/31/26 - -32.55 12/31/25 - -31.97 ROA 06/30/26 - -36.96 03/31/26 - -31.04 12/31/25 - -30.46 Current Ratio 06/30/26 - 16.24 03/31/26 - 22.61 12/31/25 - 19.85 Quick Ratio 06/30/26 - 16.24 03/31/26 - 22.61 12/31/25 - 19.85 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 4.16 03/31/26 - 4.59 12/31/25 - 4.93 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©